Fernanda Musa, MD MS
Dr. Musa is the Director of Clinical Research in Gyn Oncology at Swedish Cancer Institute in Seattle.
She obtained her medical training at Columbia University in New York and completed her residency in Ob/Gyn at New York Presbyterian Hospital – Cornell.
Her fellowship in Gyn Oncology was completed at NYU, where she also obtained an MS degree in Clinical Investigation with a thesis focusing on mTOR inhibitors and their use in ovarian cancer.
Dr. Musa is committed to improving access to clinical trials to all members of her community and removing barriers to enrollment of minority populations.
She serves as Fellowship Director for the Advanced Pelvic Surgery fellowship at Swedish. She is a member of the Society of Gynecologic Oncology board of directors and also participates on the board of directors for the Rivkin Foundation. She is on the editorial board of Gynecologic Oncology Reports, an Elsevier publication. Her research interests include cellular therapy, drug development and biomarker targeted therapy in gynecologic cancers. \
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GSKTopic:ConsultingDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Astra ZenecaTopic:Consulting/ Advisory BoardsDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MerckTopic:Speaker, Checkpoint InhibitorsDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:GSKTopic:Speaker, Shared Decision MakingDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Duality Bio/ BioNTechTopic:Advisory BoardsDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AADITopic:Advisory BoardsDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Daiichi SankyoTopic:Advisory BoardsDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:Topline BioTopic:Cervix cancer, speakerDate added:07/23/2024Date updated:07/23/2024
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:OncLiveTopic:Endometrial cancer, speaker, chair of eventDate added:07/23/2024Date updated:07/23/2024